Data gathered: November 27
Alternative Data for Neurobo Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 14,762 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Neurobo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company, provides therapies for coronavirus neurodegenerative and cardiometabolic diseases. The company is headquartered in Boston, Massachusetts.
| Price | $2.36 |
| Target Price | Sign up |
| Volume | 10,060 |
| Market Cap | $21M |
| Year Range | $2.22 - $5 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024...November 12 - Yahoo |
|
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024November 12 - Yahoo |
 |
Head-To-Head Review: Tonix Pharmaceuticals (NASDAQ:TNXP) & NeuroBo Pharmaceuticals (NASDAQ:NRBO)November 2 - ETF Daily News |
 |
NRBO stock touches 52-week low at $2.55 amid market challengesOctober 10 - Investing.com |
 |
NRBO: Positive SAD Part 1 Data; MAD Part 2 Results Expected in 1Q25…September 30 - Yahoo |
 |
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNovember 17 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 310,000 | 1.7M | -1.4M | -5.7M | -6.3M | -0.550 |
| Q2 '24 | 160,000 | 2M | -1.8M | -10M | -10M | -1.850 |
| Q1 '24 | 240,000 | 2M | -1.7M | -6.7M | -6.9M | -1.320 |
| Q4 '23 | 300,000 | 1.8M | -1.5M | -5.3M | -5.7M | -2.280 |
| Q3 '23 | 160,000 | 1.6M | -1.4M | -3.8M | -3.9M | -0.090 |
Insider Transactions View All
| DONG-A ST CO., LTD filed to buy 2,544,530 shares at $0. September 20 '24 |
| DONG-A ST CO., LTD filed to buy 3,816,795 shares at $0. September 20 '24 |
| DONG-A ST CO., LTD filed to sell 5,347,792 shares at $3.8. September 20 '24 |
| DONG-A ST CO., LTD filed to buy 5,348,229 shares at $3.1. June 25 '24 |
| DONG-A ST CO., LTD filed to buy 5,348,229 shares at $3.9. July 10 '24 |
Similar companies
Read more about Neurobo Pharmaceuticals (NRBO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Neurobo Pharmaceuticals?
The Market Cap of Neurobo Pharmaceuticals is $21M.
What is the current stock price of Neurobo Pharmaceuticals?
Currently, the price of one share of Neurobo Pharmaceuticals stock is $2.36.
How can I analyze the NRBO stock price chart for investment decisions?
The NRBO stock price chart above provides a comprehensive visual representation of Neurobo Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Neurobo Pharmaceuticals shares. Our platform offers an up-to-date NRBO stock price chart, along with technical data analysis and alternative data insights.
Does NRBO offer dividends to its shareholders?
As of our latest update, Neurobo Pharmaceuticals (NRBO) does not offer dividends to its shareholders. Investors interested in Neurobo Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Neurobo Pharmaceuticals?
Some of the similar stocks of Neurobo Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.